Cancer Clinical Trial
Official title:
Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer
Many people treated for cancer receive oral chemotherapy medications for their illness. This means that much of their cancer care occurs at home, away from a traditional oncology care setting. The purpose of this study is to explore how a Smartphone mobile application ("mobile app") can help improve the cancer treatment process in people who are prescribed oral chemotherapy medication. The investigators will explore how well the mobile app helps patients stay connected with their oncology care team, take their oral medications as prescribed, and manage their cancer-related symptoms from home. This study will be done in two phases: 1) a pilot phase to assess the feasibility of a mobile application intervention, and 2) a randomized-controlled trial to test the intervention.
Background: Over the last decade, novel targeted agents have revolutionized the delivery of
cancer care and improved survival rates, especially in those with metastatic disease. While
oral chemotherapies possess significant advantages with respect to ease of administration,
patients and caregivers receive less support for adherence and monitoring of side effects.
Therefore, novel interventions are essential to help patients communicate in a more open and
timely manner with their oncology clinicians to support adherence. As part of Phase 1 for
this Patient-Centered Outcomes Research Institute (PCORI) grant, we conducted qualitative
interviews with patients, clinicians and relevant stakeholders to inform the development of
the proposed mobile app intervention. For the randomized-controlled trial, the investigators
will recruit and randomly assign 180 adult patients prescribed oral chemotherapy to receive
either the intervention (completed smartphone mobile app) or standard care.
Objective/Hypothesis: The goals of this study are to assess the feasibility and efficacy of a
mobile application to help improve adherence to oral chemotherapy and symptom to patients
with cancer. We will administer the intervention at three cancer centers, hypothesizing that
patients with who use the mobile app will report better adherence to their oral chemotherapy
and better management of symptoms than those patients who were not assigned to the
intervention.
Specific Aims: The primary aims of this study are 1) to implement a patient-centered mobile
application to assess symptoms, side effects, and adherence to oral chemotherapy that is
feasible for use in oncology patients, and 2) to evaluate the efficacy of the mobile
application in improving patient-reported clinical outcomes.
Study Design: We will recruit and randomly assign 180 patients from the three cancer care
sites who have recently been prescribed oral chemotherapy to receive either the mobile app
intervention or standard care. Participants will be stratified by study site (i.e.
Massachusetts General Hospital (MGH), North Shore, MGH West, and Emerson Cancer Centers),
cancer type, and line of chemotherapy. This will ensure relatively equal percentages of
patients from each study site, diagnosis, and line of chemotherapy will be represented in the
treatment and control groups. The mobile app intervention which will consist of completing an
initial chemotherapy treatment plan with their oncology clinicians, responding to weekly
assessments regarding symptoms, side effects, and medication adherence, as well as receiving
personalized feedback about responses each week for 12 weeks. Medication adherence, symptom
severity, and quality of life will serve as primary outcomes, and we will collect measures of
quality cancer care as secondary targets. We will also explore whether particular patient
characteristics (i.e. cancer type, demographics) affect patient response to the mobile app
intervention.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|